Immunometabolism during Mycobacterium tuberculosis Infection

Area of Science:

• Immunology
• Microbiology
• Metabolism

Background:

• Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), infects over a quarter of the global population.
• Multidrug-resistant (MDR) and rifampicin-resistant TB strains are a significant clinical challenge, accounting for 3.4% of new and 18% of recurrent cases.
• Emerging evidence suggests drug-resistant Mtb strains can alter host metabolic reprogramming, influencing immune responses during infection.

Purpose of the Study:

• To investigate the prevalence of host metabolic reprogramming by circulating MDR Mtb strains.
• To determine the impact of drug-resistance-conferring mutations on immunometabolism in TB.
• To elucidate the mechanisms by which drug-resistant Mtb affects host immunity.

Main Methods:

• Review of existing literature on Mtb physiology, drug resistance, and host immune responses.
• Analysis of studies examining metabolic reprogramming in Mtb infection.
• Comparative analysis of immune responses to drug-susceptible versus drug-resistant Mtb strains.

Main Results:

• While direct studies on MDR-TB and metabolic reprogramming are limited, existing literature provides a foundation for understanding these interactions.
• Drug-resistance mutations in Mtb are known to alter bacterial physiology.
• Differences in immune responses to drug-resistant Mtb strains have been observed.

Conclusions:

• Drug-resistant Mtb strains likely differentially impact host immunometabolism.
• Further research is crucial to comprehensively understand the mechanisms and consequences of metabolic reprogramming by MDR-TB.
• Elucidating these mechanisms could reveal novel therapeutic targets for MDR-TB treatment.